SG11202101436SA - Anti-her2 polypeptides and methods of use thereof - Google Patents

Anti-her2 polypeptides and methods of use thereof

Info

Publication number
SG11202101436SA
SG11202101436SA SG11202101436SA SG11202101436SA SG11202101436SA SG 11202101436S A SG11202101436S A SG 11202101436SA SG 11202101436S A SG11202101436S A SG 11202101436SA SG 11202101436S A SG11202101436S A SG 11202101436SA SG 11202101436S A SG11202101436S A SG 11202101436SA
Authority
SG
Singapore
Prior art keywords
methods
her2 polypeptides
her2
polypeptides
Prior art date
Application number
SG11202101436SA
Other languages
English (en)
Inventor
Mark S Dennis
Wanda Kwan
Joseph W Lewcock
Jonathan Sockolosky
Joy Yu Zuchero
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of SG11202101436SA publication Critical patent/SG11202101436SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202101436SA 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof SG11202101436SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721505P 2018-08-22 2018-08-22
PCT/US2019/047728 WO2020041604A1 (fr) 2018-08-22 2019-08-22 Polypeptides anti-her2 et leurs méthodes d'utilisation

Publications (1)

Publication Number Publication Date
SG11202101436SA true SG11202101436SA (en) 2021-03-30

Family

ID=67989062

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101436SA SG11202101436SA (en) 2018-08-22 2019-08-22 Anti-her2 polypeptides and methods of use thereof

Country Status (15)

Country Link
US (1) US20220002436A1 (fr)
EP (1) EP3840781A1 (fr)
JP (1) JP2021534220A (fr)
KR (1) KR20210074279A (fr)
CN (1) CN113286610A (fr)
AR (1) AR115998A1 (fr)
AU (1) AU2019326545A1 (fr)
BR (1) BR112021002953A2 (fr)
CA (1) CA3141815A1 (fr)
EA (1) EA202190603A1 (fr)
IL (1) IL280922A (fr)
MX (1) MX2021001976A (fr)
SG (1) SG11202101436SA (fr)
TW (1) TW202017947A (fr)
WO (1) WO2020041604A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
EP3692070A1 (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
KR20220130678A (ko) 2019-12-23 2022-09-27 데날리 테라퓨틱스 인크. 프로그라눌린 변이체들
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
EP4229192A1 (fr) 2020-10-14 2023-08-23 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
CN118119402A (zh) * 2021-08-25 2024-05-31 戴纳立制药公司 工程化抗her2双特异性蛋白
WO2023128702A1 (fr) * 2021-12-31 2023-07-06 주식회사 아임뉴런 Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations
KR20240067001A (ko) * 2022-10-28 2024-05-16 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
WO2024123052A1 (fr) * 2022-12-08 2024-06-13 주식회사 아델 Protéine de fusion comprenant un anticorps anti-tau et un peptide et utilisation associée

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500583PA (en) * 2012-08-29 2015-04-29 Hoffmann La Roche Blood brain barrier shuttle
JP2016501881A (ja) * 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド 血液脳関門（ｂｂｂ）を透過する二重特異性結合タンパク質
WO2015191934A2 (fr) * 2014-06-11 2015-12-17 Abbvie Inc. Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
WO2016207091A1 (fr) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anticorps trispécifiques spécifiques de her2 et d'un récepteur de la barrière hémato-encéphalique et procédés d'utilisation
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
CN110520440A (zh) * 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
PT3583120T (pt) * 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados

Also Published As

Publication number Publication date
WO2020041604A1 (fr) 2020-02-27
MX2021001976A (es) 2021-06-08
JP2021534220A (ja) 2021-12-09
CN113286610A (zh) 2021-08-20
IL280922A (en) 2021-04-29
EP3840781A1 (fr) 2021-06-30
US20220002436A1 (en) 2022-01-06
CA3141815A1 (fr) 2020-02-27
BR112021002953A2 (pt) 2021-05-11
TW202017947A (zh) 2020-05-16
AR115998A1 (es) 2021-03-25
KR20210074279A (ko) 2021-06-21
AU2019326545A1 (en) 2021-03-11
EA202190603A1 (ru) 2021-07-14

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
IL280922A (en) Anti-HER2 polypeptides and uses thereof
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
HUE062927T2 (hu) Anti-TIGIT ellenanyagok és alkalmazási eljárásaik
HUE062436T2 (hu) Anti-trem2 antitestek és alkalmazási módszereik
IL269074A (en) Proteins that bind anti-TIGIT antigens and methods of using them
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL290741A (en) Antibodies against cd-96 and methods of using them
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
IL281008A (en) Anti-CD33 antibodies and methods of using them
IL283782A (en) Analosomes and methods of use
IL276187A (en) MICA/B antibodies and methods of use
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL288886A (en) Antibodies and methods of use
IL279227A (en) Anti-SIGLEC-7 antibodies and methods of using them